Cartesian Therapeutics Inc expected to post a loss of 80 cents a share - Earnings Preview

Cartesian Therapeutics

08/11/2024 23:27

* Cartesian Therapeutics Inc  RNAC.OQ   RNAC.O  is expected
to show a fall in quarterly revenue when it reports  results 
for the period ending December 31 2024
    * The Frederick Maryland-based  company is expected to
report a
76.4% decrease in revenue to $1.952 million from $8.27 million a
year ago, according to the mean estimate from 6 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Cartesian Therapeutics
Inc is
for a loss of 80 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 6.0%
in the last three months. ​
    * Wall Street's median 12-month price target for Cartesian
Therapeutics Inc is 41.00​, above​ its last closing price
of $20.76. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  -0.78       -0.79      -1.13     Missed  -42.7
 Jan. 1 2024   -0.91       -1.07      0.54      Beat    150.6
 Mar. 31 2024  -0.80       -0.88      -10.50    Missed  -1,086
                                                        .4​
 Dec. 31 2023  -0.60       -1.05      -2.10     Missed  -100
 ​​Sep.        -1.34       -1.75      -1.80     Missed  -2.9
 30 2023                                                
 Jun. 30 2023  -2.31       -2.40      -2.10     Beat    12.5​
 Jan. 1 0001   -2.62       -2.61      -4.20     Missed  -60.7
 Dec. 31 2022  -2.47       -2.19      1.20      Beat    154.9
 This summary was machine generated November 8 at 23:27 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)